Viewing StudyNCT04930094



Ignite Creation Date: 2024-05-06 @ 4:17 PM
Last Modification Date: 2024-10-26 @ 2:07 PM
Study NCT ID: NCT04930094
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-07-09
First Post: 2021-06-15

Brief Title: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo in Combination With Glucocorticoid Taper Regimen in Patients With Giant Cell Arteritis GCA
Sponsor:
Organization: Novartis

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 354
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: